Breast cancer-induced immune suppression in the sentinel lymph node is effectively countered by CpG-B in conjunction with inhibition of the JAK2/STAT3 pathway

Kim M van Pul,1,2 Ronald J C L M Vuylsteke,3 Monique T A de Beijer,1 Rieneke van de Ven,4 M Petrousjka van den Tol,2 Hein B A C Stockmann,3 Tanja D de Gruijl

ABSTRACT

Background We previously showed selectively hampered activation of lymph node-resident (LNR) dendritic cell (DC) subsets in the breast cancer (BrC) sentinel lymph node (SLN) to precede a state of profound T cell anergy. Reactivating these DC subsets by intratumoral delivery of the Toll-like receptor-9 (TLR9) agonist CpG-B could potentially offer a promising immune therapeutic strategy to combat this immune suppression and prevent disease spread. Unfortunately, CpG-B can limit its own immune stimulatory activity through direct TLR9-mediated activation of signal transducer and activator of transcription 3 (STAT3), pinpointed as a key regulator of immune suppression in the tumor microenvironment. Here, we have investigated whether in vitro exposure to CpG-B, with or without simultaneous inhibition of STAT3 signaling, could overcome immune suppression in BrC SLN.

Methods Immune modulatory effects of CpG-B (CPG7909) with or without the JAK2/STAT3 inhibitor (STAT3i) AG490 were assessed in ex vivo cultured BrC SLN-derived single-cell suspensions (N=29). Multiparameter flow cytometric analyses were conducted for DC and T cell characterization and assessment of (intracellular) cytokine profiles. T cell reactivity against the BrC-associated antigen Mammaglobin-A was determined by means of interferon-γ ELISPOT assay.

Results Although CpG-B alone induced activation of all DC subsets, combined inhibition of the JAK2/STAT3 pathway resulted in superior DC maturation (ie, increased CD83 expression), with most profound activation and maturation of LNR DC subsets. Furthermore, combined CpG-B and JAK2/STAT3 inhibition promoted Th1 skewing by counterbalancing the CpG-induced Th2/regulatory T cell response and significantly enhanced Mammaglobin-A specific T cell reactivity.

Conclusion Ex vivo immune modulation of the SLN by CpG-B and simultaneous JAK2/STAT3 inhibition can effectively overcome BrC-induced immune suppression by preferential activation of LNR DC, ultimately restoring type 1-mediated antitumor immunity, thereby securing a BrC-specific T cell response. These findings provide a clear rationale for clinical exploration of SLN-immune potentiation through local CpG/STAT3i administration in patients with BrC.

INTRODUCTION

In recent years data have accumulated to support a key role for immune-regulated pathways in breast cancer (BrC) development and response to (neo)adjuvant chemotherapy.1–2 These data have reignited interest in BrC immunotherapy, especially for triple negative (TN) and human epidermal growth factor receptor positive (HER+) BrC subtypes.3–4 Dendritic cells (DCs) are vital for the initiation of T cell-mediated antitumor responses as mature DCs are able to present tumor antigens to activate (cytotoxic) T cells. Unfortunately, tumor-derived factors suppress maturation of DC and instead promote the development of immature myeloid cells that in turn can expand regulatory T cells (Treg), all of which interfere with cytotoxic T cell functionality and contribute to tumor progression.5–6 Indeed, in a flow cytometry-based study, mapping the immune landscape in BrC sentinel lymph nodes (SLNs), we have recently shown that BrC-induced immune suppression coincides with selectively hampered activation of lymph node-resident (LNR) DC subsets, that is, plasmacytoid DC (pDC) and LNR conventional DC (LNR-cDC).7 The SLN represents the site where tumor-reactive T cells should first be primed, but also where immune suppression is expected to shape the premetastatic niche. As such, SLNs are an important target for therapeutic intervention, in particular for immune modulatory strategies aiming to bolster DC activation.
In two separate phase 2 trials in patients with melanoma, we have previously established the immune-potentiating effects of the CpG-B oligonucleotide CPG7909 (Cpg), a synthetic Toll-like receptor-9 (TLR9) agonist.\textsuperscript{8–12} Local administration of Cpg increased activation of LNR DC subsets in the SLN and enhanced local and systemic melanoma antigen (Ag)-specific CD8\textsuperscript{T} cell responses, resulting in a reduction in SLN metastases and in a significant improvement of recurrence free survival. Unfortunately, Cpg can down-modulate its own immune stimulatory activity through direct TLR9-mediated activation of signal transducer and activator of transcription 3 (STAT3), and indirectly by upregulating type I interferons (IFN-I) and STAT3-mediated factors (such as interleukin 6 (IL-6) and IL-10) that in turn can activate STAT3, creating a feedforward mechanism for STAT3 activation in non-TLR9 expressing cDC.\textsuperscript{13–16} Activation of STAT3, mostly through the JAK2/STAT3 pathway, acts as a master switch in (tumor-induced) immune suppression and systemic melanoma antigen (Ag)-specific CD8\textsuperscript{T} cell response, explaining a master switch in (tumor-induced) immune suppression.

Evidence for the therapeutic efficacy of combined TLR9 stimulation and STAT3 inhibition was previously provided by Kortylewski \textit{et al}, showing superior immune stimulatory effects of Cpg by eliminating collateral STAT3-mediated suppressive effects in a mouse-melanoma model.\textsuperscript{13,27,28} In BrC however, similar strategies have not yet been explored.

Taken together, these observations have prompted the ex vivo functional validation of combined Cpg targeting and JAK2/STAT3 inhibition as a potential treatment strategy to modulate the immune status of SLN in patients with BrC. To this end BrC SLN-derived viable single-cell samples were used to study the immune modulatory effects of Cpg with or without JAK2/STAT3 inhibition on the tumor-conditioned lymph node microenvironment ex vivo. Our findings provide a clear rationale for further clinical exploration of the immune potentiation of BrC SLN through local administration of a Cpg+JAK2/STAT3 inhibitor (STAT3i) cocktail, possibly in conjunction with existing (neo)adjuvant systemic therapies.

\section*{METHODS}

\subsection*{Patients}

From 29 female patients with clinically node negative BrC, scheduled to undergo an SLN procedure, viable cells were collected from SLN for subsequent ex vivo immune modulation. Patients with a concurrent malignancy were excluded, as well as patients actively undergoing chemotherapy or immunotherapy. In online supplemental table S1, the clinical and pathological characteristics per patient are shown, linked to the specific experiments for which the SLN of these patients were used.

\subsection*{SLN cell sampling}

Before routine histopathological examination and after confirmation by the pathologist that the SLN was suitable for cell harvesting (ie, >0.5 cm), viable cells were scraped from the SLN using a previously described method.\textsuperscript{7,29} Collected SLN cells were washed two times in complete medium (CM), comprising Iscove’s Modified Dulbecco’s Medium (IMDM) (BioWhittaker, Verviers, Belgium) supplemented with 10% heat inactivated Fetal Calf Serum (Hyclone Laboratories, Logan, Utah, USA), 100 IE/mL sodium penicillin, 100 µg/mL streptomycin sulfate, 2 mM L-glutamine (P/S/G), and 0.01 mM 2-mercaptoethanol, counted, and used directly for further ex vivo immune modulation or stored in liquid nitrogen until further use.

\subsection*{Immune modulatory agents and culture conditions}

All experiments described below were performed using BrC SLN cell samples, ex vivo cultured with or without the following immune modulatory agents (ie, culture conditions): IMDM only, that is, negative control (C1), Cpg (C2) and Cpg+JAK2/STAT3i (C3).

Synthetic Cpg-B (CPG7909, Coley Pharmaceutical Group, Wellesley, Massachusetts, USA) was added at a final concentration of 5 µg/mL, and the JAK2/STAT3i AG490 (Invitrogen, PHZ1204), hereinafter referred to as STAT3i, at a final concentration of 10 µM.\textsuperscript{30–32}

\subsection*{DC subset phenotyping}

Cell samples from 16 BrC SLNs were used for assessment of DC subset frequency and activation state after culture for 2 days (n=10) and/or 7 days (n=7) under conditions C1–C3. Of note, only one SLN was used to start both a 2-day and 7-day culture. Gating strategies (pre-culture and post-culture) used for phenotypic characterization of the analyzed DC subsets in this study are shown in online supplemental figure S1.

Before start of the SLN cell culture, a separate fraction of the cell suspension was pre-stained with monoclonal antibodies (mAbs) BCA2-FITC and CD123-PerCp-Cy5.5, in order to facilitate post-culture gating and fluorescence-activated cell sorting (FACS) analyses of the pDC subset, as membrane expression of these markers were in part lost during culture; by this pre-staining procedure the pDC subset could still be detected post-internalization of the markers and bound mAbs. Cells were resuspended at 1×10\textsuperscript{6} cells/mL in CM and cultured according to conditions C1–C3 for 2 or 7 days at 37°C in a humidified 5% CO\textsubscript{2} incubator. In the 7-day cultures, after 48 hours 300 µL medium was replaced with fresh CM with or without Cpg+STAT3i. After 2 or 7 days, supernatants were harvested and stored at −20°C for cytokine detection.
SLN cells were harvested and stained for FACS analyses as described below.

Due to variations in cell yield per SLN and between culture conditions, in four cases DC subset phenotyping was restricted to either the pDC or cDC subset(s), in two cases not all three culture conditions were tested and in three cases analysis of co-stimulatory markers was limited to CD83. Additionally, as we prioritized post-culture (C1–C3) DC subset analyses, pre-culture DC subset analyses were not performed in two cases. See online supplemental table S1.

Cytokine and chemokine analyses
Supernatants of the SLN cultures were analyzed for cytokine content using the human inflammatory cytokine bead array (CBA) kit at day 2 of culture (cytokines: IL-8, IL-1β, IL-6, IL-10, tumor necrosis factor-α (TNF-α) and IL-12p70) or the Th1/Th2 CBA kit at day 7 of culture (cytokines: IL-2, IL-4, IL-6, IL-10, TNF-α and interferon-γ (IFN-γ)). A CBA flex kit was used for detection of the chemokines CCL2, CCL5, CXCL9 and CXCL10 (day 2 and day 7). CBA analyses were performed following the manufacturer’s instructions and with the use of CBA analysis software (all from BD Biosciences).

Polyclonal T cell expansion and intracellular T cell cytokine analyses
Cells from five BrC SLNs were used for analysis of intracellular T cell cytokines after a 7-day polyclonal T cell expansion (as previously described)9 in the absence or presence of CpG and/or STAT3i. Expanded T cells were stimulated for 4–5 hours in a humidified 5% CO2 incubator at 37°C with 50 ng/mL ionomycin in the presence of 1:500 Golgiplug (BD Biosciences). After stimulation cells were harvested, washed and subsequently used for staining and FACS analyses as described below.

Flow cytometric staining and analyses
DC and T cell subsets in BrC SLN cell samples were phenotypically analyzed by four-color flow cytometry using mAbs, directed against: CD3, CD11c, CD25 (BD Biosciences, all labeled with phalloxytocyanin (APC)); CD3 and CD14 (BD Biosciences; both labeled with peridinin chlorophyll protein-cyanine 5.5 (PerCP-Cy5.5)); CD19 (BD Biosciences, labeled with PerCP); CD123 (BD Biosciences, labeled with phycoerythrin (PE)-Cy5) CD1a, CD8 (BD Biosciences) and CD40, CD83 (Beckman Coulter), all labeled with PE; CD4 (BD Biosciences), CD83 (Beckman-Coulter), CD86 (Pharmigen), BDCA2 (Miltenyi Biotec), all labeled with fluorescein isothiocyanate (FITC). We previously found CD40 to be the most sensitive activation marker for pDC8 and therefore opted to include this rather than the (for pDC) less sensitive CD86 marker. Vice versa, we preferred CD86 over CD40 as activation marker for the cDC subsets because we have previously shown that under unstimulated (ie, medium control) conditions CD40 expression level of cDC subsets is approximately 100%, and more limited upregulation of CD40 levels across cDC subsets was observed after in vivo CpG-B delivery.8 10

Staining was performed in phosphate buffered saline supplemented with 0.1% bovine serum albumin and 0.02% sodium azide for 30 min. For detection of Tregs, intracellular FoxP3 staining was performed using the eBioscience (San Diego, California, USA) PE-antihuman FoxP3 staining set following the manufacturer’s instructions. The phenotypic definitions for each of the assessed immune subsets is presented in online supplemental table S2.

STAT3 phosphorylation (pSTAT3) was assessed by intracellular staining with the PE-conjugated mAb against pSTAT3 (pY705, clone 4/pSTAT3; BD Phosflow), following the manufacturer’s instructions.

Expanded T cells from SLN cell samples were used for analysis of intracellular T cell cytokines. After stimulation (see above) cells were stained with APC-conjugated CD4 and PerCP-conjugated CD8 surface mAbs (BD Biosciences) and after fixation with Cytofix/Cytoperm solution and permeabilization with Perm/Wash solution (both from BD Biosciences) cells were stained intracellularly with PE-conjugated mAbs specific for IL-4 or IL-5 and with FITC-conjugated mAbs specific for IFNγ, TNFα or IL-2 (BD Biosciences).

Flow cytometric analyses were performed on a FACS-Calibur flow cytometer (Becton Dickinson) equipped with Cellquest data acquisition and analysis software. Data were analyzed using Kaluza analysis software. Matching isotype antibodies were used as negative controls.

Mammaglobin-A-specific T cell stimulation and IFNγ ELISPOT analyses
In 9 BrC SLNs, Ag-specific T cell IFNγ release was assessed against a pool of 21 overlapping long peptides covering the Mammaglobin-A (MAM-A) sequence (PepMixHuman MAM-A; JPT) as tumor Ag, and against a pool common recall Ags selected from human leukocyte antigen class I and II-restricted T cell epitopes from *Clostridium tetani*, Epstein-Barr virus, human cytomegalovirus and influenza A (PepMix-CEFT; JPT), as positive control.

Cell suspensions were equally divided into responder and stimulator cells. Stimulator cells were loaded with either MAM-A (1 µg/mL) or with CEFT (1 µg/mL) and 5 µg/mL β2-microglobulin (30C-cp1022U; Fitzgerald Industries). After 1–3 hours of incubation at 37°C, stimulator cells were washed to remove unbound peptides. Stimulator and responder cells were resuspended at 1×10⁶/mL IMDM+10% human pooled serum+P/S/G and were co-seeded in triplicate in a 12-well or 24-well plate. To each well, IL-2 (10 U/mL; Novartis) and IL-15 (10 ng/mL; 34-8159; eBioscience) were added and depending on the culture condition CpG2STAT3i was added. Per culture condition and peptide pool at least 3×10⁶ cells (MAM-A) and 2×10⁶ (CEFT) were used. Cells were incubated for 10 days in a humidified 5% CO₂ incubator at 37°C. Every 3–4 days the medium was replenished with IL-2 and IL-15.
Cells were harvested at day 10 and seeded in 2×3–6 replicates wells at a density of 1×10⁵/well (MAM-A) or 0.5×10⁵/well (CEFT) in a multiscreen 96-well plate coated with an IFNγcatch antibody (3420-2A; Mabtech). Cells were either rechallenged overnight with the peptides to which they were initially stimulated or cultured with a dimethylsulfoxide (DMSO) vehicle control. Of note, as a technical control, phytohemagglutinin (PHA) at a concentration of 5µg/mL was tested in duplicate (10,000 cells/well) for each plate. Next day the cells were flicked off and the plates were developed according to manufacturer's instructions. Spots were counted by an automated ELISPOT reader (AID Diagnostika). T cell ELISPOT activity (ie, Ag-specific T cell reactivity) was expressed as the number of spots per well per 1×10⁵ cells (MAM-A) or 0.5×10⁵ cells (CEFT), obtained by subtracting frequencies of spot-forming T cells in the DMSO control wells from those in the peptide-stimulated wells. Enhancement of the observed unmodulated Ag-specific T cell reactivity was considered significant when (1) the mean number of spots in the test condition (C2 or C3) was significantly higher than the mean number of spots in the control condition (C1) in a post-hoc test of a one-way analysis of variance (ANOVA) or Kruskall-Wallis test; and (2) the mean number of spots in the test condition (C2 or C3) exceeded the mean number of spots in the control condition (C1) by at least twofold.

Additionally, prior to rechallenge for the IFNγ ELISPOT assay, we used any leftover cells from the MAM-A-stimulated SLN cell cultures (n=6) to measure CD4, CD8 and Treg frequencies by means of FACS analyses.

Statistical analyses
Normal distribution was tested using the Shapiro-Wilk test. Differences were tested for statistical significance using repeated measures one-way ANOVA with post-hoc Tukey tests in case of normally distributed data, or alternatively by the Friedman test with post-hoc Dunn’s tests. In case of missing values a mixed-effects model was applied, with post-hoc multiple comparison Tukey’s test. For the assessment of differences in T cell ELISPOT activity, ordinary one-way ANOVA (normal data distribution) or Kruskall-Wallis (non-normal data distribution) with corresponding post-hoc tests were used. Data were analyzed using Prism 8 Software. P values of <0.05 were considered statistically significant.

RESULTS
AG490 can inhibit CpG-induced STAT3 activation
To ascertain that the JAK2/STAT3 inhibitor AG490 (STAT3i) could counteract CpG-induced STAT3 activation, we assessed pSTAT3 in both TLR9+ cDCs (marked by shared high expression levels of CD11c) and TLR9+ pDCs in three separate BrC SLN cell samples cultured for 24 hours, in the absence or presence of CpG or CpG+STAT3i (see figure 1A for a representative result of pSTAT3 in CD11chi cDCs at 24 hours). Although observed differences were borderline significant due to low sample number and intersample variability, clear effects were observed (see figure 1 and online supplemental figure S2). We confirmed the capability of CpG to activate STAT3 in SLN-derived DCs, in both cDCs and in pDCs, demonstrated by an approximate twofold increase in pSTAT3 expression, both by mean fluorescence intensity and percentage positive cells. Whereas pSTAT3 expression was effectively constrained to unstimulated levels by STAT3i at 24 hours for both cDCs and pDCs (figure 1B), this was not yet the case at 2 hours (online supplemental figure S2), revealing CpG-induced pSTAT3 to be rapidly initiated whereas the inhibitory effects of AG490 took longer to take effect.

Superior DC maturation, with preferential activation of LNR DC subsets after ex vivo SLN-immune modulation with CpG+STAT3i
We identified the four DC subsets as previously described in a comprehensive flow cytometry-based study mapping the immune landscape in BrC SLN. These included two migratory CD1a+ cDC subsets: CD11chCD1a-hi Langerhans cells; CD11chCD1a-hi dermal-like DCs and two LNR DC subsets: the CD1a+CD11c+CD14− LNR-cDC and the CD123+BDC2+ pDC. Gating strategies (pre-culture and post-culture) are shown in online supplemental figure S1.

Frequency and activation state of the four DC subsets after 2 days and 7 days ex vivo immune stimulation are shown in figures 2 and 3, respectively. cDC subset frequencies dropped during culture for all subsets as compared with pre-culture rates, regardless of the culture condition. Improved survival of pDC was observed by CpG exposure in the cultures (figures 2A and 3A).

Activation marker levels on the cDC subsets were increased by day 2 relative to pre-culture values, revealing maturation induction by handling and culture per se without significant enhancement by CpG with or without STAT3i (figure 2B). In contrast, activation of pDC in the medium control condition remained similar to pre-culture levels, revealing significant activation by CpG at day 2 of culture, and even more so by the combination of CpG and STAT3i, as demonstrated by the further upregulated CD83 levels. By day 7, significant upregulation of the activation markers by CpG (over the medium condition) was observed on both cDC and pDC subsets, and significantly more so for the maturation marker CD83 when CpG was combined with STAT3i (figure 3B). Overall, the immune modulatory effects of CpG, with or without STAT3i, were most profound on the LNR DC subsets (ie, LNR-cDC and pDC) (figures 2B and 3B).

Combined CpG and STAT3i results in superior Th1 skewing by counteracting CpG-induced Th2 cytokine release
Based on optimal early release of inflammatory cytokines related to DC activation and optimal release of effector cytokines on T cell activation/differentiation by day 7 of SLN cultures, supernatants taken after 2 days were used for inflammatory cytokine analyses, whereas...
supernatants taken after 7 days were used for Th1/Th2 cytokine analyses. Chemokine analyses were performed both after 2 and 7 days. At day 2, significantly increased levels of IL-6, TNFα and IL-10 were found in the supernatants of both the CpG and CpG+STAT3i conditioned SLN cell cultures (figure 4A), whereas IL-1β, IL-8 and IL-12p70 levels were unchanged compared with medium control samples (see online supplemental figure S3). Moreover, irrespective of STAT3i, significantly increased levels of all analyzed chemokines (day 2) were observed in CpG conditioned cultures. By day 7, levels of CCL5, CXCL9, CXCL10 in the CpG±STAT3i groups were even further increased over the medium control samples. Of note, by day 7 CCL2 levels in both the CpG and CpG STAT3i groups had returned to medium control levels (figure 4B). Similarly, at day 7, all Th1 cytokines were increased in the CpG and CpG+STAT3i cultures as compared with the medium control, significantly so for IL-6, TNFα and IFNγ (figure 4C), as were IL-10 levels. CpG combined with STAT3i targeting, resulted in decreased IL-4 levels compared with CpG alone (p=0.05), leading to an even more significantly skewed Th1 profile (as compared with medium control samples) when adding STAT3i to CpG as determined by IFNγ/IL-4 ratios (figure 4C).

Furthermore, the effects of CpG, with or without STAT3i, on CD4+ and CD8+ T cell-specific skewing was measured by intracellular detection of T cell cytokines after anti-CD3/CD28 plate-bound T cell expansion of SLN single-cell samples (figure 5, n=5). After expansion mean percentage (+SEM) of CD4+ and CD8+ T cells were, respectively, 54.05% (+3.83) and 6.35% (+0.55) in medium control samples; 41.29% (+4.83) and 9.81% (+1.25) in CpG conditioned samples and 41.68% (+3.21) and 10.45% (+1.25) in CpG+STAT3i conditioned samples. Whereas CpG exposure during expansion decreased IL-2 and TNFα expression, expression of IFNγ, IL-4, and IL-5 were upregulated in both CD4+ and CD8+ T cells. Remarkably, the addition of STAT3i to CpG alone further upregulated IFNγ expression but significantly downregulated IL-4 expressing CD4+ T cells (p=0.008) and IL-5 expressing CD8+ T cells (p=0.03), resulting in significant Th1 skewing compared with CpG in both CD4+ and CD8+ effector T cells (p=0.003 for CD4+ T cell IFNγ/IL-4 ratio; p=0.04 and p=0.01 for CD8+ T cell IFNγ/IL-4 and IFNγ/IL-5 ratios).

![Figure 1](image-url) Effect of CpG±AG490 on pSTAT3 levels in BrC SLN-derived cDC and pDC. Phosphorylated signal transducer and activator of transcription 3 (pSTAT3) levels (assessed by flow cytometric analysis) in the conventional DC population (phenotypically characterized by shared CD11c+) and the pDC subset measured in metastasis negative BrC SLN cell samples, cultured for 24 hours with medium, CpG or CpG+AG490. (A) Representative histogram plots of pSTAT3 fluorescence intensity (FI) levels in CD11c+ cDC (24 hours) from one of three individual BrC SLN cell samples are shown. Positive FI ranges according to fluorescence minus one control values are displayed with gray markers in each histogram. Both the mean fluorescence intensity (MFI) values and percentage pSTAT3 positive cells are displayed in boxes. (B) MFI of pSTAT3 and percentage pSTAT3 positive cells (both at 24 hours of culture) of cDCs (top bar graphs) and pDCs (bottom bar graphs) in three individual BrC SLN cell samples. Bars represent mean with SEM, with mean pSTAT3 levels (+SEM) of each culture condition and corresponding p values displayed above the error bars. BrC, breast cancer; cDCs, conventional DCs; DC, dendritic cell; pDCs, plasmacytoid DCs; SLN, sentinel lymph node; STAT3i, STAT3 inhibitor.
Combined SLN modulation with CpG and STAT3i enhances MAM-A-specific T cell-specific responses and simultaneously decreases CpG-induced Treg frequencies

Nine BrC SLN single-cell suspensions were cultured with a set of overlapping peptides covering the sequence of the BrC-associated Ag MAM-A, in the absence or presence of CpG±STAT3i, over a period of 10 days. Subsequently, Ag-specific T cell reactivity was measured on restimulation by IFNγ ELISPOT readout. Reactivity against a CETF peptide pool was determined as a measure of general immunocompetence, with Ag-specific mean spots per 100,000 wells exceeding 100 in all BrC SLN and culture conditions; in all assays technical PHA controls were positive (data not shown). All nine BrC SLNs tested for BrC-specific T cell responses corresponded to hormone receptor (HR) positive BrC which were either pT1, that is, ≤2 cm (8/9) or pT2, that is, >2–5 cm (1/9); only one SLN was metastasis positive (online supplemental table S1).

Compared with medium control samples, significantly enhanced MAM-A-specific T cell reactivity was detected in four of nine BrC SLNs after combined CpG and STAT3i modulation, whereas no such reactivity could be detected in the CpG group (figure 6A). Of the four SLNs revealing significantly enhanced MAM-A-specific T cell reactivity, all were metastasis negative and derived from pT1 BrC.

In six of nine tested samples, CD4+ and CD8+ T cell frequencies were measured prior to the IFNγ ELISPOT assay: mean percentages (±SEM) were, respectively, 50.29% (±3.04) and 9.89% (±1.26) in medium control samples; 42.64% (±2.60) and 14.36% (±1.07) in CpG conditioned samples and 42.60% (±2.72) and 15.44% (±1.11) in CpG+STAT3i conditioned samples. In both the CpG and CpG+STAT3i group, we observed significantly higher CD8/CD4 ratios as compared with the medium controls (figure 6B), which was mostly due to preferential CD8+ T cell expansion (nearly 50% relative increase).

Figure 2 Frequency and activation state of DC subsets pre/post-SLN single-cell culture (at day 2). Columns represent the different DC subsets. On the left the two CD1a+ migratory cDC subsets (LC and dDC), on the right the two LN resident DC subsets (LNR-cDC and pDC). In each dot plot, day 2 post-culture data of each culture condition (medium, CpG and CpG+STAT3i) are shown and compared. Corresponding pre-culture data are displayed in gray dots. (A) Frequencies of DC subsets, expressed as percentage of total LN cells. (B) Expression levels of maturation (CD83) and co-stimulatory/activation (CD86 for cDC and CD40 for pDC) surface receptors on different DC subsets, expressed as percentage of positive cells within each subset. Bars represent means. *p=0.01–0.05; **p=0.001–0.01; ***p=0.0001–0.001 and ****p<0.0001 in a repeated measures one-way ANOVA (or mixed-effects model in case of missing values), with post-hoc multiple comparison Tukey’s test. ANOVA, analysis of variance; cDC, conventional DC; DC, dendritic cell; dDC, dermal-like DC; LC, Langerhans cell; LN, lymph node; LNR, LN resident; pDC, plasmacytoid DC; SLN, sentinel LN; STAT3i, signal transducer and activator of transcription 3 inhibitor.
Additionally, frequencies of CD4^+CD25^hiFoxP3^hi Tregs were significantly higher in the CpG group as compared with the medium control group. On combined CpG and STAT3i modulation, these Treg frequencies were significantly decreased and comparable to medium control levels (figure 6C).

**DISCUSSION**

DCs are central regulators of antitumor immunity and as such represent prime targets of BrC-mediated immune suppression. In a previous comparative analysis of healthy breast draining LN versus SLN of patients with BrC, we showed that BrC-induced immune suppression primarily affected LNR DC subsets (ie, pDC and LNR-cDC) rather than migratory CD1a^+ DC subsets. Moreover, this suppression already occurred prior to lymph node involvement and preceded profoundly disabled T cell effector functions in tumor-involved BrC SLN, pinpointing these LNR DC subsets as pivotal regulators of cellular immune suppressive pathways and therefore as promising therapeutic targets to combat BrC-induced immune suppression and secure the induction of effective antitumor immunity. In this report we have explored an SLN-immune modulatory strategy to effectively counteract this previously described immune suppression in BrC SLN.

We cultured viable BrC SLN-derived single-cell suspensions in the absence or presence of the immune stimulatory agent CpG with or without a small-molecule inhibitor of the JAK2/STAT3 pathway, AG490 (STAT3i), and determined the effects on DC subset frequency and activation state after 2 and 7 days of culture. We believe that the 7-day cultures most accurately reflect the overall effects
Open access

of the specific immune modulatory agents (ie, CpG and CpG+STAT3i), because at day 7 external effects (ie, effects of handling and of culture per se) were minimized demonstrated by the observation that DC subset activation/maturation state in the unstimulated control group was either lower or comparable to pre-culture levels as opposed to findings at day 2. Moreover, inhibition of the JAK2/STAT3 pathway results in time-dependent activation of NF-κB which is believed to be the underlying mechanism for DC activation through JAK2/STAT3.

Figure 4  Cytokine and chemokine release in BrC SLN cell cultures. Cytokine/chemokine release levels (pg/mL) in supernatants of medium, CpG and CpG+STAT3i conditioned BrC SLN single-cell suspensions. (A) Cumulative inflammatory cytokine levels after 2 days of culture (n=11), (B) cumulative chemokine levels after 2 (n=11) and 7 days (n=6) of culture and (C) Th1/Th2 cytokine levels and Th skewing after 7 days of culture (n=6). Means (in bar graphs with SEM) are shown. *p=0.01–0.05; **p=0.001–0.01 and ***p=0.0001–0.001 in an RM one way ANOVA or Friedman with post-hoc multiple comparison Tukey’s or Dunn’s test. ANOVA, analysis of variance; BrC, breast cancer; IFNγ, interferon-γ; IL, interleukin; RM, repeated measure; SLN, sentinel lymph node; STAT3i, signal transducer and activator of transcription 3 inhibitor; TNFα, tumor necrosis factor-α.
This notion, combined with previous findings that CpG-induced pDC activation allows the indirect (and thus delayed) activation of non-TLR9 expressing cDC subsets through induction of local cytokine release from pDC, most notably IFN-γ. This provides additional support that the 7-day cultures also allow these delayed effects to become detectable. In keeping with this, CpG-induced pDC activation was already detectable and significant by day 2, whereas CpG-induced activation of the cDC subsets was only detectable and significant by day 7.

Based on results from the 7-day cell cultures, CpG exposure induced activation (ie, increased CD86 or CD40 expression) of all DC subsets, whereas maturation (marked by CD83 expression) was most profoundly induced in LNR DC subsets (ie, pDC and LNR-cDC). These results are in line with our previous findings that local CpG administration in patients with melanoma led to the preferential recruitment and maturation of these LNR DC subsets. In our current study, we additionally assessed the immune modulatory effect of combined STAT3 targeting. The direct antitumor effect of STAT3i alone has been established in several pre-clinical BrC studies. However, while in these studies STAT3i was assessed in the context of targeting the primary tumor itself where STAT3 activation is abundantly present, our study design was specifically intended to target BrC draining SLN. As the BrC SLN in our study were derived from patients in the early stage and were mostly metastases free, baseline STAT3 activation was likely less present than in these tumor models but was predominantly induced by CpG administration (as also illustrated by figure 1). Indeed, in three separate BrC SLN cultures no activating effects of STAT3i only were observed (online supplemental figure S4). Therefore, our approach of combining STAT3i with CpG administration was specifically intended to counterbalance CpG-induced STAT3 activation and associated Th2 skewing and Treg expansion.

Adding STAT3i to CpG further enhanced the maturation state (CD83 expression) of all DC subsets, but most significantly of the LNR-cDC and pDC subsets. Whereas pDCs are involved in IFN-γ-driven boosting of cytotoxic T cell responses, the LNR-cDC subset has been linked to cross-priming of cytotoxic T cells. We previously showed that under steady state conditions this LNR-cDC subset preferentially expressed BDC3 and CLEC9a compared with its migratory cDC counterparts and both we and other groups have linked this BDC3+ DC population (designated cDC1) to cross-priming abilities, vital to the elicitation of an effective antitumor CD8+ T cell-mediated immune response. More recent, as yet unpublished, studies from our lab employing multi-parameter FACS panels of up to 15 markers have shown the LNR-cDC from these SLN suspensions to consist mostly (>75%) of more cDC2-like DC with co-expression of both CD1c and BDCA3, but also of a minority of CD1c−CD141hi cDC1-like cells (<25%), see online supplemental figure S5; our current data suggest that both are equally activated by CpG±STAT3i. In light of this, our finding that combined CpG and STAT3i targeting can counteract (more effectively than CpG alone) BrC-induced suppression of all these LNR DC subsets would point to the likely induction of a more robust T cell response.

To further investigate this, Ag-specific effector T cell frequencies against MAM-A, a BrC-associated Ag expressed in up to 80% and not restricted to BrC subtype, were quantified in BrC SLN by means of an IFNγ ELISPOT assay. We show that CpG can enhance MAM-Aspecific T cell responses, only when administered in combination with STAT3i. In line with these findings both Th1/Th2 cytokine release and intracellular T cell cytokine analyses point to a significantly skewed Th1 response on CpG+STAT3i targeting. The observed increased Th1/Th2 ratios on combined CpG and STAT3i conditioning mainly resulted from preventing CpG-enhanced levels

![Figure 5](image-url)
levels of the typical Th1-associated chemokines CXC9 and CXC10 which mediate CD4+ Th1 and CD8+ T cell recruitment to the TME, and of the chemokines CCL2 and CCL5 which have been described to mediate DC-T cell interactions in LNs and cDC1 recruitment, both vital processes for efficient CD8+ T cell priming and the elicitation of a Th1 antitumor response. Of note, when produced by tumor-suppressed immune cells or by tumor cells themselves, CCL2 and CCL5 can also promote recruitment of immune-suppressive cells to tumor sites, such as tumor-associated macrophages and myeloid-derived suppressive cells. As such, the protumor or antitumor roles of CCL2 and CCL5 appear to be highly context (ie, disease and anatomic localization) dependent. As in this study chemokines were assessed in SLN draining from patients with early-stage BrC and not in the context of the tumor itself, presumably here CCL2 and CCL5 would most prominently exert their T cell priming and antitumor functions, and conceivably even more so under proinflammatory conditions induced by CpG.

Combined, these cytokine and chemokine data illustrate that while CpG in fact controls the initiation of the (Th1) proinflammatory response, the effect of adding STAT3i to CpG activation was mainly limited to counter-balancing of the CpG-induced Th2 response, ultimately promoting type 1-mediated antitumor immunity and leading to the induction of a BrC-specific T cell response. This would also fit with the observed lack of changes in IL-12 content in 2-day supernatants between the medium control and CpG+STAT3i conditioned SLN cell cultures (online supplemental figure S3), which may be explained by the fact that CpG-B directly impacts pDC but not cDC and that cDC rather than pDC are a major source of IL-12. Of note, in a group of four SLN samples we observed increased IFNγ release on culture with CpG, most likely secreted by pDC, which also remained unaffected by the addition of STAT3i (online supplemental figure S6).
by AG490 was delayed (see figure 1B and online supplemental figure S2) most likely because it occurs through an indirect mechanism (ie, by blocking JAK2-mediated pSTAT3), probably allowing early IL-10 release to occur. As a consequence, decreased real-time IL-10 release by immune cell subsets on indirect inhibition of the STAT3 pathway might be missed because of early CpG-induced and STAT3-activation-mediated IL-10 release dominating the cumulatively measured IL-10 levels. A similar explanation could also account for the lack of decreased IL-6 release in response to combined CpG and STAT3i treatment. The induction of a Th2 (and IL-10) response by CpG was further accompanied by increased Treg levels on CpG addition alone. Importantly, combining CpG administration with STAT3i did prevent this increase.

Kortylewski et al previously provided evidence for the therapeutic efficacy of CpG combined with STAT3 targeting.13 27 28 Similarly to our findings, they showed increased CpG-induced DC maturation, T cell activation and generation of tumor Ag-specific T cells by eliminating collateral STAT3-mediated suppressive effects in a mouse-melanoma model. Importantly, they also provided evidence for a reciprocal mechanism underlying the therapeutic effects of combined CpG administration and STAT3 targeting, that is, that by inhibiting STAT3 signaling not only the brake had been lifted from CpG-mediated immune responses (by reducing the immune suppressive potential mediated by CpG), but also that the antitumor effect of STAT3i was enhanced by the induction of pro-inflammatory conditions by CpG.

To our knowledge we are the first to ascertain the therapeutic potential of combined CpG+STAT3i targeting in BrC. Furthermore, whereas BrC immunotherapy to date has mainly focused on TN and HER2+ BrC,34 here we show that also in HR positive BrC, immune-regulated pathways can be targeted to restore BrC-related immune suppression and induce a BrC-specific T cell response. This is highlighted by our finding that out of nine BrC SLNs, all corresponding to HR− BrC subtypes, in four cases significantly increased MAM-A-specific T cell responses could be detected after ex vivo SLN immune modulation with CpG+STAT3i.

Due to increased presence of tumor-infiltrating lymphocytes (TIL) and their prognostic significance in TN and HER2+ BrC,55 56 these subtypes have been regarded as more immunogenic than non-T cell-inflamed HR+ BrC subtypes. Evidence is accumulating that in non-T cell-inflamed tumors, innate immune pathways required for recruitment/activation of DCs and T cell priming/homing into the tumor bed (and thus presence of TIL) might not be engaged, and that for all of these steps in the immune activation cycle to function properly, a IFN-I proinflammatory response is required.46 57 Although exact molecular mechanisms responsible for this immune exclusion are still being unraveled, activation of the STAT3 pathway has been implicated as a potential candidate.46 In our endeavor to target BrC-mediated immune suppression of LNR DC subsets in the SLN, we have shown that CpG targeting combined with STAT3i can not only efficiently reactivate these LNR DC subsets but can in fact also induce a proinflammatory response. Combined this might convert an immune-excluded BrC into an immune-inflamed tumor, independent of BrC subtype, and thus increase the efficacy of immune checkpoint blockade. Although in this study the population of BrC SLN which was tested for BrC-specific T cell responses was limited to the HR+ BrC subtype, CpG+STAT3i mediated induction of a BrC-specific T cell response will likely not be limited to HR+ BrC subtypes. Whereas JAK2/STAT3 signaling can occur in all BrC subtypes, it is most often associated with TN and HER2+ subtypes.21 39 Indeed, we previously showed that BrC-related immune suppression preferentially affected LNR DC subsets (ie, pDC and LNR-cDC) and that their suppressed state was more profound in HR− BrC subtypes.7 Moreover, we here show that the DC stimulatory effect of CpG+STAT3i was most profound in these LNR DC subsets and although sample sizes were too small for definitive subgroup analyses, when comparing HR+ versus HR− draining SLN similar increases in activation/maturation marker expression levels on CpG+STAT3i treatment (day 7) were observed (online supplemental figure S7).

In conclusion, our findings provide a clear rationale for clinical exploration of BrC SLN immune potentiation through local CpG+STAT3i administration for all BrC subtypes. In view of increasing evidence that immune-regulated pathways influence the response to (neo)adjuvant chemotherapy, we anticipate clinical benefit not only of combining this immune stimulatory cocktail with immune checkpoint blockade, but also with (neo)adjuvant chemotherapy.

**Author affiliations**

1Medical Oncology—Cancer Center Amsterdam, Amsterdam UMC—VUMC location, Amsterdam, The Netherlands
2Surgical Oncology, Amsterdam UMC—VUMC location, Amsterdam, The Netherlands
3Surgery, Spaanse Gasthuis, Haarlem, The Netherlands
4Medical Oncology and Otolaryngology-Head and Neck Surgery—Cancer Center Amsterdam, Amsterdam UMC—VUMC location, Amsterdam, The Netherlands

**Twitter** Rieneke van de Ven @DeRieneke

**Acknowledgements** We thank Sinéad Lougheed and Tara Muijlwijk for excellent technical assistance.

**Contributors** This study was conceived by KMW and TvdG. Lab protocols and experiments were designed by KMW, RvdV and TvdG. KMW recruited patients, performed experiments and analyzed data. MTAdB performed experiments and analyzed data. RvdV and TvdG supervised lab work. MPvdT, RJCLMV and HBACS were clinical supervisors in the participating hospitals. KMW and TvdG wrote the manuscript. All authors critically reviewed and approved the final manuscript.

**Funding** This work was supported by grants from A Sister’s Hope (HBACS and TvdG) and the Dutch Cancer Society (KWF VU2015-7864, RvdV, TvdG).

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Ethics approval** This study was approved by the Institutional Review Board of the VU University medical center (IRB permit number 2012-421). SLN samples were collected and handled according to ethical and medical guidelines described in the Code of Conduct for Proper Use of Human Tissue of the Dutch Federation of

---

van Pul KM, et al. J Immunother Cancer 2020;8:e000761. doi:10.1136/jitc-2020-000761
Biomedical Scientific Societies with written informed consent from the patients prior to SLN sampling.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. Datasets used and analyzed during the current study are available from the corresponding author upon reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Tanja D de Grujì http://orcid.org/0000-0003-1464-8978

REFERENCES

1. Andre F, Dieci MV, Dubsky P, et al. Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res 2013;19:28–33.
2. DeNardo DG, Brennan DJ, Rexhepi E, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011;1:54–67.
3. Emens LA. Breast cancer immunotherapy: facts and hopes. Clin Cancer Res 2016;22:451–20.
4. Disis ML, Stanton SE. Immunotherapy in breast cancer: an introduction. Breast 2018;37:196–9.
5. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012;12:253–68.
6. Janakivashili N, Bonnotte B, Katsanis E, et al. The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance. Clin Dev Immunol 2011;2011:1–14.
7. van Pul KM, Vuytskeste RCLJM, van de Ven R, et al. Selectively hampered activation of lymph node-resident plasmacytoid dendritic cells precedes profound T cell suppression and metastatic spread in the breast cancer sentinel lymph node. J Immunother Cancer 2019;7:1–14.
8. Molenkamp BG, Van LPAM, Meijer S. Intra-dermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients intradermal CpG-B activates both plasmacytoid and myeloid. Clin Cancer Res 2007;13:2961–9.
9. Molenkamp BG, Slijije BJ, van Leeuwen PAM, et al. Local administration of PF-351267h CpG-B instigates tumor-specific CD8+ T cell reactivity in melanoma patients. Clin Cancer Res 2008;14:4532–42.
10. Slijije BJ, van den Hout MFCM, Koster BD, et al. Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDC3/CD11c(+) Dendritic Cells and Enhanced Cross-Presentation. Cancer Immunol Res 2015;3:495–505.
11. Koster BD, van den Hout MFCM, Slijije BJ, et al. Local adjuvant treatment with low-dose CpG-B offers durable protection against disease recurrence in clinical stage I-II melanoma: data from two randomized phase II trials. Clin Cancer Res 2017;23:5679–86.
12. van den Hout MFCM, Slijije BJ, Santegoets SJAM, et al. Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node. Cancer Immunol Immunother 2016;65:405–15.
13. Kortylewski M, Kujawski M, Herrmann A, et al. Toll-Like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy. Cancer Res 2009;69:2497–505.
14. Yu H, Lee H, Herrmann A, et al. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 2014;14:736–46.
15. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007;7:41–51.
16. Tsai M-H, Pai L-M, Lee C-K. Fine-Tuning of type I interferon response by STAT3. Front Immunol 2019;10:1–10.
17. Nefedova Y, Huang M, Kusmartsev S, et al. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol 2004;172:464–74.
18. Moseman EA, Liang X, Dawson AJ, et al. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol 2004;173:4433–42.
19. Masjedi A, Hashemi V, Hojjat-Farsangi M, et al. The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer. Biomed Pharmacother 2018;108:1415–24.
20. Banerjee K, Resat H. Constitutive activation of STAT3 in breast cancer cells: a review. Int J Cancer 2016;138:2570–8.
21. Berishaj M, Gao SP, Ahmed S, et al. Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res 2007;9:1–8.
22. Jones LM, Broz ML, Ranger JJ, et al. Stat3 establishes an immunosuppressive microenvironment during the early stages of breast carcinogenesis to promote tumor growth and metastasis. Cancer Res 2016;76:1146–28.
23. Diz N, Minton S, Cox C, et al. Activation of STAT3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated Src and survivin expression. Clin Cancer Res 2006;12:20–8.
24. Liu L-YD, Chang L-Y, Kuo W-H, et al. Prognostic features of signal transducer and activator of transcription 3 in an ER(+) breast cancer model system. Cancer Inform 2013;13:21–45.
25. Hsieh F-C, Cheng G-I, et al. Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem Biophys Res Commun 2005;335:292–9.
26. Kortylewski M, Swiderski P, Herrmann A, et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol 2009;27:925–32.
27. Herrmann A, Kortylewski M, Kujiwski M, et al. Targeting STAT3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res 2010;70:7455–64.
28. Vuytskeste RCLJM, van Leeuwen PAM, Meijer S, et al. Sampling tumor-draining lymph nodes for phenotypic and functional analysis of dendritic cells and T cells. Am J Pathol 2002;161:19–26.
29. Lanuti P, Bertagolino V, Pierdomenico L, et al. Enhancement of TRAIL cytotoxicity by AG-490 in human ALL cells is characterized by downregulation of c-FLIP and c-FLIP-2 through inhibition of JAK2/STAT3. Cell Res 2009;19:1079–89.
30. Garcia R, Bowman TL, Niu G, et al. Constitutive activation of STAT3 by the Src and JAK2 tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001;20:2498–513.
31. Oosterhoff D, Lougheed S, van de Ven R, et al. Tumor-Mediated inhibition of human dendritic cell differentiation and function is consistently counteracted by combined p38 MAPK and STAT3 inhibition. Oncogene 2008;27:1035–45.
32. Wang J, Wang X, Hussain S, et al. Distinct roles of different NF-kappa B subunits in regulating inflammatory and T cell stimulatory gene expression in dendritic cells. J Immunol 2007;178:6777–88.
33. Gursel M, Verhelyi D, Kliman DM. CpG oligodeoxynucleotides include human monocytic and plasmacytoid dendritic cells to mature into functional dendritic cells. Eur J Immunol 2002;32:2617–22.
34. Schust J, Sperli B, Hollis A, et al. Statick: a small-molecule inhibitor of STAT3 activation and dimethylation. Chem Biol 2006;13:1235–42.
35. Dave B, Landis MD, Dobrolecki LE, et al. Correction: selective small molecule STAT3 inhibitor reduces breast cancer tumor-initiating cells and improves cure rate free survival in a Human-Xenograft model. PLoS One 2012;7:1–8.
36. Tkach M, Coria L, Rosemblit C, et al. Targeting STAT3 induces senescence in tumor cells and elicits prophylactic and therapeutic inhibiting responses against breast cancer growth mediated by NK cells and CD4+ T cells. J Immunol 2012;189:1162–72.
37. Pinto A, Rega A, Crother TR, et al. Plasmacytoid dendritic cells and their therapeutic activity in cancer. Oncoimmunology 2012;1:726–34.
38. van de Ven R, van den Hout MFCM, Lindenberg JJ, et al. Characterization of four conventional dendritic cell subsets in human skin-draining lymph nodes in relation to T-cell activation. Blood 2011;118:2502–10.
Open access

40 Segura E, Amigorena S. Cross-Presentation by human dendritic cell subsets. *Immunol Lett* 2014;158:73–8.

41 Jongbloed SL, Kassianos AJ, McDonald KJ, et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. *J Exp Med* 2010;207:1247–60.

42 Watson MA, Dintzis S, Darrow CM, et al. Mammaglobin expression in primary, metastatic, and occult breast cancer. *Cancer Res* 1999;59:3028–31.

43 Baker E, Whiteoak N, Hall L, et al. Mammaglobin-A, VEGFR3, and Ki67 in human breast cancer pathology and five year survival. *Breast Cancer* 2019;13:20–3.

44 Hall BM, Tran G, Verma ND, et al. Activation of naive CD4+CD25+FOXP3+Treg by specific autoantigen and Th2 cytokines IL-4 and IL-5 induces autoantigen specific Treg that inhibit EAE. *J Immunol* 2019;202:116.16.

45 Vilgelm AE, Richmond A. Chemokins modulate immune surveillance in tumorigenesis, metastasis, and response to immunotherapy. *Front Immunol* 2019;10:6–8.

46 Spranger S, Gajewski TF. Tumor-Intrinsic oncogene pathways mediating immune avoidance. *Oncoimmunology* 2016;5:1–7.

47 Dal Secco V, Soldani C, Debrat C, et al. Tunable chemokine production by antigen presenting dendritic cells in response to changes in regulatory T cell frequency in mouse reactive lymph nodes. *PLoS One* 2009;4:1–9.

48 Bakos E, Thaiss CA, Kramer MP, et al. Ccr2 regulates the immune response by modulating the interconversion and function of effector and regulatory T cells. *J Immunol* 2017;198:4659–71.

49 González-Martín A, Gómez L, Lustgarten J, et al. Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells. *Cancer Res* 2011;71:5455–66.

50 Böttcher JP, Bonavita E, JP B, et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer article NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. *Cell* 2018;172:1022–37.

51 Lazenec G, Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. *Trends Mol Med* 2010;16:133–44.

52 Nizzoli G, Krietsch J, Weick A, et al. Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T-cell responses. *Blood* 2013;122:932–42.

53 Mahnke YD, Brodie TM, Sallusto F, et al. The who’s who of T-cell differentiation: human memory T-cell subsets. *Eur J Immunol* 2013;43:2797–809.

54 Samarasinghe R, Tailor P, Tamura T, et al. Induction of an anti-inflammatory cytokine, IL-10, in dendritic cells after Toll-like receptor signaling. *J Interferon Cytokine Res* 2006;26:893–900.

55 Denkert C, von Minckwitz G, Brase JC, et al. Tumor-Infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. *J Clin Oncol* 2015;33:983–91.

56 Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. *Ann Oncol* 2014;25:1544–50.

57 Bonaventura P, Shekarian T, Alcazer V, et al. Cold tumors: a therapeutic challenge for immunotherapy. *Front Immunol* 2019;10:1–10.

58 Qin J-J, Yan L, Zhang J, et al. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review. *J Exp Clin Cancer Res* 2019;38:1–16.